<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROTRIPTYLINE HYDROCHLORIDE- protriptyline hydrochloride tablet </strong><br>Roxane Laboratories, Inc<br></p></div>
<h1><span class="Bold">Protriptyline Hydrochloride Tablets, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_70ad3d51-2553-40ef-9a3b-770cde055b95"></a><a name="section-1"></a><p></p>
<h1>Rx only</h1>
</div>
<div class="Warning">
<a name="ID_52bb6c19-368d-46e2-97e5-65dc6eb575d3"></a><a name="section-2"></a><p></p>
<h1>Suicidality and Antidepressant Drugs</h1>
<p class="First"><span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Protriptyline hydrochloride is not approved for use in pediatric patients. (See <a href="#i4i_contraindications_id_87e75c51-45dc-4996-b763-c7776421ac06">WARNINGS</a>: <a href="#ID_76c45d02-5982-4979-864b-12528f1a92e9">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a>, </span><span class="Bold"><a href="#i4i_warnings_id_2a20f9da-0025-4ff1-a98b-80831e7e45f4">PRECAUTIONS</a></span><span class="Bold">: <a href="#_Information_for_Patients">Information for Patients</a>, and <a href="#i4i_warnings_id_2a20f9da-0025-4ff1-a98b-80831e7e45f4">PRECAUTIONS</a>: <a href="#_Pediatric_Use">Pediatric Use</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_faeb2de2-037e-406b-a4f1-595810f3c85b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Protriptyline HCl is <span class="Italics">N</span>-methyl-5H dibenzo[<span class="Italics">a,d</span>]-cycloheptene-5-propanamine hydrochloride. Its molecular formula is C<span class="Sub">19</span>H<span class="Sub">21</span>N•HCl and its structural formula is:</p>
<div class="Figure">
<a name="id-956640183"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&amp;name=image-01.jpg">
</div>
<p>Protriptyline HCl, a dibenzocycloheptene derivative, has a molecular weight of 299.84. It is a white to yellowish powder that is freely soluble in water and soluble in dilute HCl. Protriptyline HCl is supplied as 5 mg or 10 mg tablets. Inactive ingredients are anhydrous lactose, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7b2db9ab-bd97-4d61-88f2-48ba3def524f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Protriptyline hydrochloride is an antidepressant agent. The mechanism of its antidepressant action in man is not known. It is not a monoamine oxidase inhibitor, and it does not act primarily by stimulation of the central nervous system</p>
<p>Protriptyline has been found in some studies to have a more rapid onset of action than imipramine or amitriptyline. The initial clinical effect may occur within one week. Sedative and tranquilizing properties are lacking. The rate of excretion is slow.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_103bcfeb-d08b-4878-9762-dc38264bb833"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Protriptyline Hydrochloride Tablets, USP are indicated for the treatment of symptoms of mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_87e75c51-45dc-4996-b763-c7776421ac06"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Protriptyline Hydrochloride Tablets, USP are contraindicated in patients who have shown prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it.</p>
<p>It should not be given concomitantly with a monoamine oxidase inhibiting compound. Hyperpyretic crises, severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. Protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved.</p>
<p>Protriptyline Hydrochloride Tablets, USP are contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions including prolongation of the QT interval, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and conduction system disturbances.</p>
<p>This drug should not be used during the acute recovery phase following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_2a20f9da-0025-4ff1-a98b-80831e7e45f4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_76c45d02-5982-4979-864b-12528f1a92e9"></a><a name="section-6.1"></a><p></p>
<h2>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Bold">Table 1</span>. </p>
<table width="100%">
<caption><span>Table 1</span></caption>
<col width="33%">
<col width="67%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle"><p class="First">Age Range</p></td>
<td class="Botrule Toprule" align="center" valign="middle">
<p class="First">Drug-Placebo Difference in Number of Cases of </p>
<p>Suicidality per 1000 Patients Treated</p>
</td>
</tr>
<tr>
<td class="Toprule" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">Increases Compared to Placebo </p></td>
</tr>
<tr>
<td align="center" valign="middle"><p class="First">&lt;18</p></td>
<td align="center" valign="middle"><p class="First">14 additional cases </p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First">18 to 24</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">5 additional cases</p></td>
</tr>
<tr>
<td class="Toprule" valign="middle"></td>
<td class="Toprule" align="center" valign="middle"><p class="First">Decreases Compared to Placebo </p></td>
</tr>
<tr>
<td align="center" valign="middle"><p class="First">25 to 64 </p></td>
<td align="center" valign="middle"><p class="First">1 fewer case </p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Underline">&gt;</span>65</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">6 fewer cases</p></td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. </p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. </p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. </p>
<p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see <a href="#i4i_adverse_effects_id_fee9786f-9dce-49f2-940d-f5114edbf48d">ADVERSE REACTIONS</a>: <a href="#ID_5719b72d-b1a9-43dd-aa19-5ed56e3beb0c">Withdrawal Symptoms</a> for a description of the risks of discontinuation of protriptyline). </p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. </span>Prescriptions for protriptyline should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2b63d9dc-9a86-4902-94db-d194fc31008c"></a><a name="section-6.2"></a><p></p>
<h2>Screening Patients for Bipolar Disorder</h2>
<p class="First">A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that protriptyline hydrochloride is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</p>
<p>Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds.</p>
<p>Protriptyline should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and, because of its autonomic activity, in patients with a tendency to <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, or increased intraocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> may occur more frequently with protriptyline than with other antidepressant drugs. Protriptyline should be used with caution in elderly patients and patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>; such patients should be observed closely because of the tendency of the drug to produce <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and prolongation of the conduction time. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred with drugs of this class.</p>
<p>On rare occasions, hyperthyroid patients or those receiving thyroid medication may develop <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> when this drug is given.</p>
<p>In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> or overdosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_abd2de30-27db-4d45-892a-22acf41da5ff"></a><a name="section-6.3"></a><p></p>
<h2>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">The pupillary dilation that occurs following use of many antidepressant drugs including protriptyline may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_309e4c3d-38e1-4a7b-91c1-a857d95a01e2"></a><a name="section-6.4"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Safe use in pregnancy and lactation has not been established; therefore, use in pregnant women, nursing mothers or women who may become pregnant requires that possible benefits be weighed against possible hazards to mother and child.</p>
<p>In mice, rats, and rabbits, doses about ten times greater than the recommended human doses had no apparent adverse effects on reproduction.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c2e9de99-6110-4006-846e-1d4c9b546356"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_75f1520e-2b93-4c0e-90eb-f535740f995e"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">When protriptyline is used to treat the depressive component of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms may be aggravated. Likewise, in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-depressive <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, depressed patients may experience a shift toward the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase if they are treated with an antidepressant drug. <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">Paranoid delusions</span>, with or without associated <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, may be exaggerated. In any of these circumstances, it may be advisable to reduce the dose of protriptyline or to use a major tranquilizing drug concurrently.</p>
<p>Symptoms, such as <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, may be aggravated in overactive or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients.</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> in depressed patients remains during treatment and until significant remission occurs. This type of patient should not have access to large quantities of the drug.</p>
<p>Concurrent administration of protriptyline and electroshock therapy may increase the hazards of therapy. Such treatment should be limited to patients for whom it is essential.</p>
<p>Discontinue the drug several days before elective surgery, if possible.</p>
<p>Both elevation and lowering of blood sugar levels have been reported.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_086e93f2-3851-43b3-8444-50758d34ba67"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Prescribers or other health professionals should inform patients, their families and their caregivers about the benefits and risks associated with treatment with protriptyline hydrochloride and should counsel them in its appropriate use. A patient Medication Guide About "Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Mental Illness, and Suicidal Thoughts or Actions" is available for protriptyline hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking protriptyline hydrochloride.</p>
<p>Patients should be advised that taking protriptyline can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pre-existing <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is almost always open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> because angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, when diagnosed, can be treated definitively with iridectomy. Open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is not a risk factor for <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> procedure (e.g., iridectomy), if they are susceptible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b1c07034-0bce-49cf-9d97-5e96682e731d"></a><a name="section-7.3"></a><p></p>
<h2>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients, their families and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.</p>
<p>While on therapy with protriptyline, patients should be advised as to the possible impairment of mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_24f85593-0bf9-4e5b-8258-f294a3482e5b"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">When protriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.</p>
<p><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> has been reported when tricyclic antidepressants are administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.</p>
<p>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine. Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen. Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.</p>
<p>Tricyclic antidepressants may enhance the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking ULTRAM (tramadol hydrochloride).</p>
<p>Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c0754de9-3943-46a1-a6a9-3f6b52c83ceb"></a><a name="section-7.5"></a><p></p>
<h2>Drugs Metabolized by Cytochrome P450 2D6</h2>
<p class="First">The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).</p>
<p>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective seratonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</p>
<p>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_d9a84166-e0a6-44ad-8844-ba923020aba2"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in the pediatric population have not been established (see <span class="Bold">BOX WARNING</span> and <a href="#i4i_warnings_id_2a20f9da-0025-4ff1-a98b-80831e7e45f4">WARNINGS</a><span class="Bold">: </span><a href="#ID_76c45d02-5982-4979-864b-12528f1a92e9">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a><span class="Bold">).</span> Anyone considering the use of protriptyline hydrochloride in a child or adolescent must balance the potential risks with the clinical need.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_db8c415b-3abf-4ac3-a2d9-9e10e66ca335"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of protriptyline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <a href="#i4i_warnings_id_2a20f9da-0025-4ff1-a98b-80831e7e45f4">WARNINGS</a>, <a href="#_Refi4i_dosage_admin_id_a592d4f3-5d0a-42">DOSAGE AND ADMINISTRATION</a> and <a href="#_Refi4i_adverse_effects_id_fee9786f-9dce">ADVERSE REACTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_fee9786f-9dce-49f2-940d-f5114edbf48d"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Within each category the following adverse reactions are listed in order of decreasing severity. Included in the listing are a few adverse reactions which have not been reported with this specific drug. However, the pharmacological similarities among the tricyclic antidepressant drugs require that each of the reactions be considered when protriptyline is administered. Protriptyline is more likely to aggravate <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and produce cardiovascular reactions such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, particularly <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>.</p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional states</span> (especially in the elderly) with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>; <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, panic, and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p><span class="Bold">Neurological:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>; <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of extremities; <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH</span> (antidiuretic hormone) secretion; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; alteration in EEG patterns.</p>
<p><span class="Bold">Anticholinergic:</span> <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span>; <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, delayed micturition, dilatation of the urinary tract; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, disturbance of accommodation, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and rarely associated sublingual <span class="product-label-link" type="condition" conceptid="316084" conceptname="Lymphadenitis">adenitis</span>.</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Drug fever</span>; <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, photosensitization (avoid excessive exposure to sunlight); <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (general, or of face and tongue).</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>; <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; peculiar taste; <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>; black tongue.</p>
<p><span class="Bold">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, increased or decreased libido; <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> in the male; <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span> and <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> in the female; <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span>; elevation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of blood sugar levels.</p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> (simulating obstructive); altered liver function; <span class="product-label-link" type="condition" conceptid="4152183" conceptname="Parotid swelling">parotid swelling</span>; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss; <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>; perspiration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5719b72d-b1a9-43dd-aa19-5ed56e3beb0c"></a><a name="section-8.1"></a><p></p>
<h2>Withdrawal Symptoms</h2>
<p class="First">Though not indicative of addiction, abrupt cessation of treatment after prolonged therapy may produce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7d0986c-eb8a-49c3-8066-37d086009909"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> may occur from overdosage with this class of drugs. Multiple drug ingestion (including alcohol) is common in deliberate tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. As management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity develop rapidly after tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, therefore, hospital monitoring is required as soon as possible.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_32e713e5-bf33-406c-a098-ce114636791c"></a><a name="section-9.1"></a><p></p>
<h2>Manifestations</h2>
<p class="First">Critical manifestations of overdosage include: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity.</p>
<p>Other signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, disturbed concentration, transient <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, or any of the symptoms listed under <a href="#_Refi4i_adverse_effects_id_fee9786f-9dce">ADVERSE REACTIONS</a><span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d07027b-2288-4be1-9585-fc3b41946447"></a><a name="section-9.2"></a><p></p>
<h2>Management</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fbe8518d-7a87-4c12-b2bb-71664168eb40"></a><a name="section-9.2.1"></a><p></p>
<h3>General</h3>
<p class="First">Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or conduction blocks, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. There are case reports of patients succumbing to fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> late after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. These patients had clinical evidence of significant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> prior to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug levels should not guide management of the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_43ed152b-1802-4212-bdc4-b047e91e693d"></a><a name="section-9.2.2"></a><p></p>
<h3>Gastrointestinal<span class="Bold"></span>Decontamination</h3>
<p class="First">All patients suspected of a trycyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d3f99de5-ec21-44c3-b6a6-9dd85447ccda"></a><a name="section-9.2.3"></a><p></p>
<h3>Cardiovascular</h3>
<p class="First">A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be used to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may also be used. Concomitant use of <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be done with extreme caution, with frequent pH monitoring. A pH &gt;7.60 or a pCO2 &lt;20 mmHg is undesirable. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Dysrhythmias</span> unresponsive to sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> therapy/<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide and procainamide).</p>
<p>In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> generally have been reported as ineffective in tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6105e979-54c6-4c97-93df-c2f587432a6e"></a><a name="section-9.2.4"></a><p></p>
<h3>CNS</h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, early intubation is advised because of the potential for abrupt deterioration. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a5027d6e-9eca-4aa9-95c8-1f7051e532e4"></a><a name="section-9.3"></a><p></p>
<h2>PsychiatricFollow-up</h2>
<p class="First">Since overdosage is often deliberate, patients may attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> by other means during the recovery phase. Psychiatric referral may be appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a04edd3a-5dc1-4420-9839-48de9b43c960"></a><a name="section-9.4"></a><p></p>
<h2>PediatricManagement</h2>
<p class="First">The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a592d4f3-5d0a-420c-a895-793fba1a1e34"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerance.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb06506c-ba4c-4ada-b17d-928b777a5ecc"></a><a name="section-10.1"></a><p></p>
<h2>Usual Adult Dosage</h2>
<p class="First">Fifteen to 40 mg a day divided into 3 or 4 doses. If necessary, dosage may be increased to 60 mg a day. Dosages above this amount are not recommended. Increases should be made in the morning dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_197a894d-8da5-4b86-a405-468f2f0f1c90"></a><a name="section-10.2"></a><p></p>
<h2>Adolescent and Elderly Patients</h2>
<p class="First">In general, lower dosages are recommended for these patients. Five mg 3 times a day may be given initially, and increased gradually if necessary. In elderly patients, the cardiovascular system must be monitored closely if the daily dose exceeds 20 mg.</p>
<p>When satisfactory improvement has been reached, dosage should be reduced to the smallest amount that will maintain relief of symptoms.</p>
<p>Minor adverse reactions require reduction in dosage. Major adverse reactions or evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> require prompt discontinuation of the drug.</p>
<p>The safety and effectiveness of protriptyline in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c8534504-3ecf-4e2b-a2e1-e4cbb3fc3f82"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Protriptyline Hydrochloride Tablets, USP are supplied as white, round, biconvex tablets. The 5 mg tablet is debossed with "54 306" on one side and plain on the other. The 10 mg tablet is debossed with "54 694" on one side and plain on the other.</p>
<table width="100%">
<col width="18%">
<col width="82%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="First">0054-0210-25</p></td>
<td><p class="First">5 mg, white tablet, bottle of 100</p></td>
</tr>
<tr class="Botrule Last">
<td><p class="First">0054-0211-25</p></td>
<td><p class="First">10 mg, white tablet, bottle of 100</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_42b69d34-5b30-41b2-ae89-e1e6053ccaaa"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight container as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8dd11ea-7667-4f20-b023-933f76955fc0"></a><a name="section-12"></a><p></p>
<h1>METABOLISM</h1>
<p class="First">Metabolic studies indicate that protriptyline is well absorbed from the gastrointestinal tract and is rapidly sequestered in tissues. Relatively low plasma levels are found after administration, and only a small amount of unchanged drug is excreted in the urine of dogs and rabbits. Preliminary studies indicate that demethylation of the secondary amine moiety occurs to a significant extent, and that metabolic transformation probably takes place in the liver. It penetrates the brain rapidly in mice and rats, and moreover that which is present in the brain is almost all unchanged drug.</p>
<p>Studies on the disposition of radioactive protriptyline in human test subjects showed significant plasma levels within 2 hours, peaking at 8 to 12 hours, then declining gradually.</p>
<p>Urinary excretion studies in the same subjects showed significant amounts of radioactivity in 2 hours. The rate of excretion was slow. Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2992ea5b-f5e7-4ede-b8b5-28f070fa2a6a"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"> ULTRAM is a registered trademark of Ortho-McNeil Pharmaceutical Inc.</p>
<p>Roxane Laboratories, Inc.</p>
<p>Columbus, Ohio 43216</p>
<p><span class="Bold">10004773/04 Revised May 2014</span></p>
<p> © RLI, 2014</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_b1d1938b-2c8e-491c-a5ef-70b7acdf1769"></a><a name="section-14"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f670cc30-8c3f-48a0-b4c9-1f8cf58c69b1"></a><a name="section-14.1"></a><p></p>
<h2>Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions </h2>
<p class="First">Read the Medication Guide that comes with you or your family member’s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <span class="Bold">Talk to your, or your family member’s, healthcare provider about: </span></p>
<p>• all risks and benefits of treatment with antidepressant medicines </p>
<p>• all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness </p>
<p> </p>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and other serious mental illnesses, and suicidal thoughts or actions? </span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal  thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions. </dd>
<dt>3.</dt>
<dd>
<span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? </span><dl>
<dt>•</dt>
<dd>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. </dd>
<dt>•</dt>
<dd>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. </dd>
<dt>•</dt>
<dd>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. </dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: </span></p>
<dl>
<dt> </dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </dd>
<dt> </dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </dd>
<dt> </dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt> </dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </dd>
<dt> </dt>
<dd>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> </dd>
<dt> </dt>
<dd>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </dd>
<dt> </dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </dd>
<dt> </dt>
<dd>acting aggressive, being angry, or violent </dd>
<dt> </dt>
<dd>acting on dangerous impulses </dd>
<dt> </dt>
<dd>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) </dd>
<dt> </dt>
<dd>other unusual changes in behavior or mood</dd>
<dt> </dt>
<dd>visual problems: <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, changes in vision, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in or around the eye </dd>
</dl>
<p><span class="Bold">What else do I need to know about antidepressant medicines? </span></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider. </span>Stopping an antidepressant medicine suddenly can cause other symptoms.</dd>
<dt> </dt>
<dd>
<span class="Bold">Visual problems:</span> Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</dd>
<dt> </dt>
<dd>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses. </span>It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</dd>
<dt> </dt>
<dd>
<span class="Bold">Antidepressant medicines have other side effects. </span>Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</dd>
<dt> </dt>
<dd>
<span class="Bold">Antidepressant medicines can interact with other medicines. Know all of the medicines that you or your family member takes.</span> Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider. </dd>
<dt> </dt>
<dd>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children. </span>Talk with your child’s healthcare provider for more information. </dd>
</dl>
<p>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.</p>
<p>Roxane Laboratories, Inc.</p>
<p>Columbus, Ohio 43216</p>
<p><span class="Bold">10004773/04 Revised May 2014</span></p>
<p>© RLI, 2014</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e1fc15b9-b51b-4983-90f5-d27c98babd61"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0054-0211-25</p>
<div class="Figure">
<a name="id750702158"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Protriptyline HCl Tabs\Labels\FPL 10004772_03.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_01f0f8d2-5d98-41dd-90de-cdaeeb76ecb3"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0054-0210-25</p>
<div class="Figure">
<a name="id-2114188817"></a><img alt="\\eu.boehringer.com\depts\col\groups\DRA-MA\LABELING\XML Files\Protriptyline HCl Tabs\Labels\FPL 10004771_03.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&amp;name=image-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROTRIPTYLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">protriptyline hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0210</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROTRIPTYLINE HYDROCHLORIDE</strong> (PROTRIPTYLINE) </td>
<td class="formItem">PROTRIPTYLINE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54306</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0210-25</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078913</td>
<td class="formItem">09/16/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROTRIPTYLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">protriptyline hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0054-0211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROTRIPTYLINE HYDROCHLORIDE</strong> (PROTRIPTYLINE) </td>
<td class="formItem">PROTRIPTYLINE HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;694</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0054-0211-25</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078913</td>
<td class="formItem">09/16/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Roxane Laboratories, Inc
							(833490464)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Roxane Laboratories, Inc (833490464)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane Inc</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">MANUFACTURE(0054-0210, 0054-0211)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2e1c79e2-ae88-4cc0-8db3-85e520a42c58</div>
<div>Set id: 700abc58-9362-4ef5-9d7a-dd3c4d364d0a</div>
<div>Version: 3</div>
<div>Effective Time: 20140523</div>
</div>
</div> <div class="DistributorName">Roxane Laboratories, Inc</div></p>
</body></html>
